ATOVAQUONE AND PROGUANIL HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	Proficient Rx LP	63187-879-16	16 TABLET, FILM COATED in 1 BOTTLE (63187-879-16)	2011-08-18
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	Proficient Rx LP	63187-879-24	24 TABLET, FILM COATED in 1 BOTTLE (63187-879-24)	2011-08-18
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	BluePoint Laboratories	68001-245-00	100 TABLET, FILM COATED in 1 BOTTLE (68001-245-00)	2014-03-13
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	BluePoint Laboratories	68001-245-15	2 BLISTER PACK in 1 CARTON (68001-245-15) / 12 TABLET, FILM COATED in 1 BLISTER PACK (68001-245-14)	2014-03-13
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	Glenmark Pharmaceuticals Inc.,USA	68462-402-01	100 TABLET, FILM COATED in 1 BOTTLE (68462-402-01)	2015-04-08
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	Glenmark Pharmaceuticals Inc.,USA	68462-404-01	100 TABLET, FILM COATED in 1 BOTTLE (68462-404-01)	2011-09-15
Glenmark Pharms Ltd	ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride	TABLET;ORAL	091211	ANDA	Glenmark Pharmaceuticals Inc.,USA	68462-404-67	2 BLISTER PACK in 1 CARTON (68462-404-67) / 12 TABLET, FILM COATED in 1 BLISTER PACK (68462-404-44)	2011-09-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key suppliers for Atovaquone and Proguanil Hydrochloride active pharmaceutical ingredients (APIs) and finished drug products. It details manufacturing capabilities, regulatory standing, and market presence to inform procurement and strategic partnership decisions.

Who are the Primary API Manufacturers for Atovaquone and Proguanil Hydrochloride?

Atovaquone and Proguanil Hydrochloride, a combination antimalarial and anti-Pneumocystis pneumonia (PCP) drug, is manufactured by a concentrated group of API producers globally. These suppliers vary in production volume, regulatory approvals, and geographical focus.

Key API Suppliers:

Cipla Limited: An established Indian pharmaceutical company with a significant API manufacturing base. Cipla has a long history of producing antimalarial APIs, including those for Atovaquone and Proguanil Hydrochloride. Their facilities are Good Manufacturing Practice (GMP) compliant and have received approvals from various international regulatory bodies.
Sun Pharmaceutical Industries Ltd.: Another major Indian pharmaceutical producer with extensive API manufacturing capabilities. Sun Pharma is known for its broad product portfolio and robust regulatory compliance. They possess dedicated facilities for complex API synthesis.
IPCA Laboratories Limited: A significant player in the Indian API market, IPCA Laboratories manufactures a wide range of APIs, including those used in antimalarials. Their operations are subject to stringent quality control measures and international regulatory standards.
TEVA Pharmaceutical Industries Ltd.: While primarily known for its generic finished drug products, Teva also has a substantial API manufacturing division. Teva's global manufacturing network and experience in regulatory affairs position them as a potential supplier for Atovaquone and Proguanil Hydrochloride APIs.
Bristol-Myers Squibb: As the original innovator of the combination drug (marketed as Malarone®), Bristol-Myers Squibb has historically manufactured the API. While their direct API manufacturing for the generic market may have shifted, their expertise and historical involvement are noteworthy.
Eisai Co., Ltd.: This Japanese pharmaceutical company has manufacturing sites that produce various APIs. Their involvement in the production of specific antimalarial agents positions them as a potential, though less commonly cited, supplier.

API Production Metrics:

Data on precise production volumes for specific APIs like Atovaquone and Proguanil Hydrochloride is proprietary. However, industry estimates suggest that the leading Indian manufacturers (Cipla, Sun Pharma, IPCA) collectively account for the majority of the global supply for many generic APIs, including this combination. Production capacity is typically measured in metric tons per annum.

Regulatory Approvals:

Suppliers are expected to hold relevant regulatory certifications to supply these APIs for pharmaceutical formulations. Key approvals include:

US Food and Drug Administration (FDA) Inspection: For products intended for the U.S. market.
European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of Suitability (CEP): Essential for European Union market access.
WHO Prequalification: Critical for procurement by international health organizations like the Global Fund and UNICEF, particularly for malaria-endemic regions.
National Regulatory Agency Approvals: Such as those from India's Central Drugs Standard Control Organisation (CDSCO) and other relevant authorities.

What is the Market for Atovaquone and Proguanil Hydrochloride Finished Dosage Forms?

The market for Atovaquone and Proguanil Hydrochloride finished dosage forms is primarily driven by its use as a prophylactic and treatment for malaria, and as a treatment for Pneumocystis jirovecii pneumonia (PCP) in immunocompromised individuals. The demand is bifurcated between the branded product and its generic counterparts.

Branded Product:

Malarone® (Atovaquone/Proguanil Hydrochloride): Originally developed by GlaxoSmithKline (GSK), the marketing rights have been complex and have involved other entities over time. It remains a significant product in the malaria prevention market.

Generic Market Landscape:

The generic market for Atovaquone and Proguanil Hydrochloride tablets has expanded significantly following patent expiries. This has led to increased competition and a broader range of suppliers.

Key Generic Finished Product Manufacturers:

Teva Pharmaceutical Industries Ltd.: A leading global generic drug manufacturer. Teva markets generic versions of Atovaquone/Proguanil Hydrochloride tablets in various regions, leveraging its extensive distribution network and regulatory expertise.
Mylan N.V. (now Viatris): Another major player in the generics space. Viatris offers generic Atovaquone/Proguanil Hydrochloride tablets in key markets, focusing on affordability and accessibility.
Cipla Limited: Beyond API production, Cipla also manufactures finished dosage forms of Atovaquone/Proguanil Hydrochloride, often targeting emerging markets and specific tenders.
Sun Pharmaceutical Industries Ltd.: Similar to Cipla, Sun Pharma integrates API production with finished formulation manufacturing, supplying generic Atovaquone/Proguanil Hydrochloride tablets globally.
Ipsen S.A.: While not a primary generic manufacturer in the traditional sense for this product, Ipsen has been involved in the distribution and marketing of specific formulations or in certain geographical regions.
Intas Pharmaceuticals Ltd.: An emerging player with growing global reach in generic pharmaceuticals. Intas manufactures and markets generic Atovaquone/Proguanil Hydrochloride tablets, particularly in Europe and emerging markets.

Market Drivers and Dynamics:

Malaria Prevalence: Regions with high malaria transmission rates (Sub-Saharan Africa, Southeast Asia, Latin America) are significant demand centers for antimalarial formulations.
HIV/AIDS Population: The global HIV/AIDS epidemic, particularly in regions where access to advanced treatments may be limited, drives demand for PCP prophylaxis with Atovaquone/Proguanil Hydrochloride.
Government Procurement: Public health initiatives and tenders from national health ministries and international organizations (e.g., Global Fund, WHO) are substantial market components.
Pricing Pressures: Intense competition among generic manufacturers leads to significant price reductions, impacting revenue but increasing accessibility.
Regulatory Scrutiny: Stringent quality and bioequivalence requirements for generic approvals necessitate robust manufacturing and testing protocols.

Dosage Strengths and Formulations:

The most common formulation is a tablet containing 250 mg of Atovaquone and 100 mg of Proguanil Hydrochloride. Pediatric formulations (e.g., chewable tablets) are also available.

What are the Patent and Exclusivity Considerations for Atovaquone and Proguanil Hydrochloride?

The patent landscape for Atovaquone and Proguanil Hydrochloride is mature, with key composition of matter and method of treatment patents having expired in major markets. Generic competition is well-established.

Key Patent Expirations:

Composition of Matter Patents: The foundational patents covering the Atovaquone and Proguanil Hydrochloride combination expired years ago in the U.S. and Europe, paving the way for generic entry. Specific dates vary by country and patent family. For instance, the original U.S. patents for Malarone® expired in the early to mid-2010s.
Method of Treatment Patents: Patents related to specific uses, such as prophylaxis or treatment of specific conditions, have also largely expired or been successfully challenged.
Formulation Patents: While some newer or improved formulations might have been patented, these are typically narrower in scope and have less impact on the broad market for standard tablet formulations.

Regulatory Exclusivities:

Data Exclusivity: For new drug applications (NDAs) for original formulations, periods of data exclusivity are granted, preventing generic approval based on the innovator's clinical trial data. However, this is less relevant for long-established generics.
Patent Certifications (e.g., Hatch-Waxman Act in the U.S.): Generic manufacturers must certify the status of relevant patents when filing their abbreviated new drug applications (ANDAs). This often involves challenging or navigating existing patents, leading to patent litigation.

Current Patent Landscape:

The current patent landscape is characterized by:

Limited to No Remaining Composition of Matter Patents: For standard formulations.
Focus on Process Patents: Some innovation may exist in novel or improved manufacturing processes for the APIs or finished products, which could offer a competitive advantage but not necessarily market exclusivity against established methods.
Potential for Niche Formulations: Patents on unique delivery systems, combination therapies with other drugs, or specific pediatric formulations might still be active but do not broadly impact the core generic market.

Implications for Business:

Generic Competition Dominates: The market is highly competitive with numerous generic suppliers.
Price is a Key Differentiator: Success hinges on cost-effective manufacturing and supply chain efficiency.
Regulatory Compliance is Paramount: Maintaining GMP certifications and successfully navigating global regulatory requirements is critical.
Intellectual Property Strategy: Focus shifts from blocking competition via composition of matter patents to potential process improvements or niche formulation patents.

How is the Supply Chain Structured for Atovaquone and Proguanil Hydrochloride?

The supply chain for Atovaquone and Proguanil Hydrochloride involves the synthesis of two distinct APIs, their subsequent combination, and formulation into finished dosage forms. This multi-stage process is managed by a network of specialized manufacturers and distributors.

Stages of the Supply Chain:

Raw Material Sourcing: Procurement of basic chemical precursors for Atovaquone and Proguanil synthesis. This stage involves chemical suppliers who may be distinct from the API manufacturers.
API Manufacturing (Atovaquone): Specialized chemical synthesis of Atovaquone. This is a complex multi-step process requiring expertise in organic chemistry. Key manufacturers are located in India and, to a lesser extent, China.
API Manufacturing (Proguanil Hydrochloride): Synthesis of Proguanil Hydrochloride. This is generally considered a less complex synthesis than Atovaquone. Major API manufacturers produce both APIs.
API Blending and Quality Control: The two APIs are blended in precise ratios (250 mg Atovaquone to 100 mg Proguanil Hydrochloride per standard dose) and subjected to rigorous quality control testing to ensure purity, potency, and uniformity.
Finished Dosage Form (FDF) Manufacturing: The blended API is formulated into tablets. This involves excipients such as binders, fillers, disintegrants, and lubricants. FDF manufacturers also conduct further quality control and stability testing.
Packaging and Labeling: Tablets are packaged into blisters, bottles, or other appropriate containers, with labeling compliant with regulatory requirements of target markets.
Distribution and Logistics: Finished products are distributed through wholesalers, distributors, and directly to pharmacies, hospitals, and government tenders globally. Cold chain management is generally not required for this product.

Key Supply Chain Participants:

API Manufacturers: As identified previously (Cipla, Sun Pharma, IPCA, Teva). These companies may produce one or both APIs.
Contract Development and Manufacturing Organizations (CDMOs): Some finished product manufacturers may outsource API synthesis or FDF manufacturing to specialized CDMOs.
Formulators: Companies that specialize in converting APIs into finished dosage forms.
Distributors and Wholesalers: Entities responsible for moving products from manufacturers to end-users.
Regulatory Bodies: FDA, EMA, WHO, and national health authorities provide oversight and approval at various stages.

Geographical Concentration:

API Production: Heavily concentrated in India, with some capacity in China.
Finished Product Manufacturing: More geographically dispersed, with significant players in India, the U.S., Europe, and other regions.

Risk Factors and Mitigation:

Single Sourcing: Reliance on a single API supplier for either Atovaquone or Proguanil Hydrochloride creates vulnerability. Mitigation involves qualifying multiple suppliers and maintaining buffer stock.
Regulatory Non-Compliance: A single facility's GMP failure can disrupt supply. Diversification of manufacturing sites and strong quality management systems are essential.
Geopolitical Instability: Political or trade issues in key manufacturing regions can impact supply chains.
Quality Issues: API or FDF recalls due to quality defects can be costly and damaging. Robust in-house quality assurance and supplier audits are critical.

Key Takeaways

The global supply of Atovaquone and Proguanil Hydrochloride APIs is dominated by a few key Indian manufacturers, notably Cipla, Sun Pharma, and IPCA Laboratories, who possess extensive GMP-compliant manufacturing capabilities and hold international regulatory approvals.
The finished dosage form market is characterized by strong generic competition following patent expiries, with major players including Teva, Viatris, Cipla, and Sun Pharma. Demand is driven by malaria prophylaxis and treatment, and PCP management.
The patent landscape is mature, with primary composition of matter patents expired in key markets, allowing for widespread generic production. Intellectual property focus is now on process improvements and niche formulations.
The supply chain is multi-staged, from raw material sourcing to API synthesis (both Atovaquone and Proguanil Hydrochloride), FDF manufacturing, and global distribution, with India serving as a central hub for API production.

Frequently Asked Questions

What are the primary regulatory bodies that approve Atovaquone and Proguanil Hydrochloride manufacturing sites? Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and its member state authorities, and the World Health Organization (WHO) for prequalification. National regulatory agencies in importing countries also play a crucial role.
Are there any significant Chinese API manufacturers for Atovaquone and Proguanil Hydrochloride that hold international approvals? While China is a significant global API producer, the primary suppliers with established international regulatory track records and large volumes for Atovaquone and Proguanil Hydrochloride are predominantly Indian. Some Chinese companies may produce these APIs, but their regulatory acceptance for major Western markets or WHO prequalification may be less widespread compared to Indian counterparts.
What is the typical lead time for sourcing Atovaquone and Proguanil Hydrochloride APIs from major suppliers? Lead times can vary but typically range from 3 to 6 months for bulk API orders. This includes production scheduling, manufacturing, quality control testing, and logistics. For novel or specialized formulations, lead times can be longer.
What are the main risks associated with the supply chain for this drug combination? Key risks include reliance on single-source API suppliers, geopolitical instability affecting manufacturing regions, potential quality control failures leading to recalls, and fluctuations in raw material costs.
Beyond malaria and PCP, are there other significant therapeutic uses for Atovaquone and Proguanil Hydrochloride? While malaria prevention and treatment, and PCP prophylaxis, are the primary established indications, Atovaquone has also been investigated and used for other parasitic infections, though these are generally not the primary drivers of the large-scale market for the combination product. Proguanil is a dihydrofolate reductase inhibitor, and its mechanism has applications in other areas, but its use in combination with Atovaquone is specifically targeted at the aforementioned indications.

Citations

[1] GlaxoSmithKline. (n.d.). Malarone® Prescribing Information. Retrieved from [Specific GSK Malarone PI link - if publicly available and relevant, otherwise abstract]

[2] U.S. Food and Drug Administration. (n.d.). Drug Shortages. Retrieved from www.fda.gov/drugshortages

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from www.edqm.eu

[4] World Health Organization. (n.d.). WHO Prequalification Programme. Retrieved from www.who.int/prequal

[5] Indian Pharmacopoeia Commission. (n.d.). Indian Pharmacopoeia. Retrieved from [Specific IPC link - if publicly available and relevant, otherwise abstract]

Suppliers and packagers for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE